| Summary: | 碩士 === 國立交通大學 === 管理學院碩士在職專班科技管理組 === 95 === Medicine is very important to mankind. It is closely associated with human health and life quality. As we all aware, medicine has been changed according to the evolution of internal/external environment. Inevitably, the Taiwan pharmaceutical industry has faced tremendous pressure these years. Over 90 percentage of companies are small sizes, their respective annual revenue is not more than NT$300MM. Due to traditional prefer of being a boss of a small firm, Taiwan Pharma company is difficult to integrate with each other. On the other hand, most of the companies in US, Europe or even Japan are going thru M&A to increase their competitiveness. Therefore, What is the winning growth strategy to break through the "red ocean" for pharmaceutical industries in Taiwan？In addition, what kind of innovation thought to enhance the international competitive strength to achieve the "blue ocean" strategy of industries besides lacking of resource and integration capability？
To face the more intensified industrial environment, M&A and alliance are most important strategy to enhance a competition advantage for corporation growth. The environment of pharmaceutical in Taiwan, it has been getting all supports from government, academia and research institute. On top of upgrade of regulation in Departments of Health (DOH), clinical trial in medical center, Ministry of Economic Affair and National Science Council (NSC) not only provide fund and incentives, but also get full supports of seed money from the Development Fund, Executive Yuan. In past ten years, it had made good progress. However the pharmaceutical companies should pay more efforts to improve the shape. Such as to create an international competitiveness.
This paper is a first case study of M&A between a drug marketing company and a R/D oriented speciality pharmaceutical company on developing new drug. We have analyses the case through an observation to construct the proposition and use a methodology of focus interview for conclusion. We expect to find a role model and learn how the innovative thinking could enhance the corporation value and competitiveness. Further to speed up the corporation growth, we're going to analyses the growth strategy and take an action plan.
After study, we need to propose a set of recommendations for Taiwan pharma, which is small but beautiful business model through government’s promotion on the alliance of marketing network and establishing the industrial partnership to co-promotion for export. In order to have the competitiveness, it's important to upgrade the software/hardware of facilities to FDA standard. Moreover, Apply to the concept on diffusion and collaboration of innovation in R/D. At the same time, use a balanced product portfolio to actively look for the alliance and investment with speciality pharmaceutical company in US. Furthermore, Take advantage of government resources and collaboration with pharma industrial to jointly participate in research and development on drugs. To make sure achieve the fruitful synergy on new drugs development as well use an external growth strategy as M&A to speedy expand the marketplace for creating the revenue growth purpose.
|
|---|
